



Journal Articles: Extended Use

Overview

The contraceptive implant and intrauterine contraceptive devices are the most effective reversible methods available in the United States. Recent data indicate that the implant and some IUD devices remain efficacious for longer than the length of use that is indicated in the package inserts for the products. Data that is presented supports use of these products beyond the length of use stated in the package insert for patients who are interested in extending their use of the contraceptive implant beyond 3 years (up to 5 years) and beyond 5 years (up to 7 years) for the 52mg levonorgestrel IUD. These data show no decrease in efficacy in the additional years of use in patients of all BMIs.

Successful Completion

This course offers 1.0 contact hours. To receive contact hours, participants must complete the course with a satisfactory grade of 80% or higher on the quiz and complete the Evaluation/Request for Credit form. CNE and certificates of completion will be available immediately upon passing the course and submitting the evaluation. CHES certificates will be emailed within four weeks of submitting the evaluation.

Objectives

- Discuss use of the etonogestrel implant for up to five years in obese patients
- Explain the proposed mechanism of action for the etonogestrel implant
- Identify the length of use of 52 mg IUDs in each product's package insert
- Describe the effectiveness of the 52 mg IUD (Mirena) 6 and 7 years after placement

Conflict of Interest

In accordance with continuing education guidelines, speakers and planning committee members have disclosed financial relationships with commercial interests that may create a potential conflict of interest.

Disclosures

Author Disclosures: Moazzam Ali, Luis Bahamondes, Valeria Bahamondes, Arlete Fernandes, Cassia T. Juliato, Ilza Monteiro, Mitchell D. Creinin, Rolf Jansen, Robert M. Starr, Joga Gobburu, Mathangi Gopalakrishnan, Andrea Olariu, Justine P. Wu, Sarah Pickle, Colleen McNicholas, DO, MSCI; Erin Swor, MD; Leping Wan, MPH; Jeffrey F. Peipert, MD, PhD, Patrick Rowe, Tim Farley, Alexandre Peregoudov, Gilda Piaggio, Simone Boccard, Sihem Landoulsi, Olav Meirik have nothing to disclose.

Planning Committee Disclosures: Sharon Colbert, Angela Bolen, Charlotte Curtis, Viannella Halsall, Martha Loftgreen and Tracy VanVlack have nothing to disclose. Jacki Witt serves on the advisory panel for Afaxys (Resolved).

Commercial Support/Sponsorship:

There is no commercial support for this training.

Non-Endorsement of Products:

The University of Missouri-Kansas City School of Nursing and Health Studies and ANCC do not approve or endorse any commercial products associated with this activity.

Enduring Materials – CNE and CHES contact hours will be awarded for this program through December 31, 2018.

Accreditation

The University of Missouri-Kansas City School of Nursing and Health Studies is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This program offers up to 1.0 contact hour for this activity.

Sponsored by UMKC School of Nursing and Health Studies, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This webinar is

designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours.

Contact Angela Bolen at bolena@umkc.edu if you have questions regarding continuing education credit.